Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

The planned trial offers treatment cohorts for patients with full cytologic relapse (R/R ALL - Cohort 1), as well as for patients with molecular failure/relapse (MRD+ ALL - Cohort 2). Basically, the study aims to develop data for optimization of first-line therapy of T-ALL, either by modification of standard induction with Isatuximab or by establishing a post-induction therapy for eradication of MRD and thereby evaluates in parallel two different strategies.

Trial Details

NCT ID
NCT06648889
Phase
PHASE2
Sponsor
Goethe University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Isatuximab
Locations (sample)
  • Augsburg, Germany|48.37154,10.89851
  • Berlin, Germany|52.52437,13.41053
  • Bremen, Germany|53.07582,8.80717
  • Dresden, Germany|51.05089,13.73832
  • Düsseldorf, Germany|51.22319,6.77927

Key Eligibility Criteria

  • Patients with CD38 positive T-ALL/T-LBL
  • Either: In relapse or with primary refractory disease defined as ≥5% blasts in bone marrow cytology or ≥1% minimal residual disease (MRD)
  • Or: Extramedullary relapse or primary refractory disease confirmed by standard imaging with measurable target leasions
  • after at least three chemotherapy cycles (induction I-II, consolidation I) with the following additional specifications:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →